Όλο το DSpace

Πλοήγηση ανά Θέμα "Hypercholesterolemia"

Αποτελέσματα 1-3 από 3

    • Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 

      Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)
      Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ...

    • Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk 

      Milionis H., Barkas F., Ntaios G., Papavasileiou V., Vemmos K., Michel P., Elisaf M. (2016)
      Background/purpose A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors alirocumab and evolocumab. We aimed to investigate the ...

    • Risk Factor Assessment in a Greek Cohort of Patients With Large Abdominal Aortic Aneurysms 

      Makrygiannis G., Mourmoura E., Spanos K., Roussas N., Kuivaniemi H., Sakalihasan N., Tsezou A., Giannoukas A. (2019)
      Environmental and genetic risk factors contribute to the etiology of abdominal aortic aneurysms (AAAs). Matrix metalloproteinases (MMPs) have been associated with the pathophysiology of AAAs. A prospective, nonrandomized ...